Updated: 2-ArriVent’s oral lung cancer therapy fails in late-stage clinical trial, shares plunge

路透社2026/10/06 13:21

Show original

In the first paragraph, stock information was added. Paragraphs 2 to 8 provide a detailed introduction to the disease and the clinical trial situation. Reuters, Oct. 6 - ArriVent BioPharma (AVBP.O) said on Tuesday that its oral therapy for treating rare lung cancer failed to meet its primary goal of delaying disease progression in a late-stage clinical trial, leading to its shares plunging by 63% in premarket trading. The therapy, firmonertinib, targets previously untreated advanced non-small cell lung cancer (NSCLC) patients who carry a gene mutation called the EGFR exon 20 insertion, which can promote cancer growth. This mutation accounts for about 0.5% to 1% of all NSCLC cases. NSCLC represents about 85% of all lung cancer cases. In the trial, according to independent reviewers, the 240mg dosage developed by ArriVent extended median progression-free survival to 11 months, compared to 9.5 months in the chemotherapy group. Chief Executive Officer Bing Yao stated that the improvement in progression-free survival (defined as the length of time patients live without worsening or spread of disease) was not significant. "These disappointing results are not what we had hoped for, especially for patients with EGFR exon 20 insertion-mutant NSCLC who are in urgent need of more effective treatments," said Yao. The company is evaluating the full data set to determine the most suitable development path for firmonertinib. ArriVent stated that no new safety signals were observed in the trial. The therapy has already been approved in China for non-small cell lung cancer patients carrying specific mutations. (For the convenience of non-English language speakers, Reuters has automated the translation of its reporting into several other languages. Due to possible errors or missing context in automated translation, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters accepts no responsibility for any damages or losses caused by the use of the automated translation feature.)

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Additional stock information is included in paragraph 1; paragraphs 2 to 8 provide detailed information on the disease and clinical trial.

Reuters, October 6 - ArriVent BioPharma (AVBP.O) said on Tuesday that its oral therapy for the treatment of rare lung cancer failed to meet its primary goal of delaying disease progression in a late-stage clinical trial, sending the company's shares plunging 63% in premarket trading.

The therapy (firmonertinib) targets patients with previously untreated advanced non-small cell lung cancer (NSCLC) who carry a genetic alteration known as EGFR exon 20 insertion mutation, which may drive cancer growth.

This mutation accounts for about 0.5% to 1% of all NSCLC cases. Non-small cell lung cancer makes up about 85% of all lung cancer cases.

In the trial, according to an independent review, the 240-mg dose therapy developed by ArriVent extended median progression-free survival to 11 months, compared to 9.5 months for the chemotherapy group.

Chief Executive Officer Bing Yao said the improvement in progression-free survival—that is, the time patients live without disease worsening or spreading—was not significant.

“These disappointing results are not what we had hoped for, especially for patients with EGFR exon 20 insertion mutation NSCLC who are in urgent need of more effective treatment options.”

Yao said the company is evaluating the full data set to determine the most appropriate development path for firmonertinib.

ArriVent said no new safety signals were observed in the trial.

The therapy has already been approved in China for NSCLC patients carrying specific mutations.

(To assist non-English speakers, Reuters offers its reports through automated translation into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the translated text, which is provided solely for the convenience of readers. Reuters accepts no liability for any damage or loss arising from the use of this automated translation service.)

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Updated to market close Firmus, backed by Nvidia, cancels $5 billion IPO plan; tech stocks see their biggest weekly gain in a week; Benchmark index posts gains for the second consecutive week Jasmeen Ara Islam Shaikh, Reuters, October 9 – Australian stocks rose on Friday as bargain hunters bought shares after a recent benchmark pullback; at the same time, Firmus’s decision to shelve its $5 billion IPO plan triggered an inflow of funds into local software stocks. The benchmark S&P/ASX 200 .AXJO rose 0.6% on Friday to close at 8,716.6 points after two consecutive days of declines. For the week, the index rose 0.4%, posting gains for a second straight week. Globally, comments from US President Trump that the US would pause strikes against Iran ahead of the November midterm elections provided a slight lift to market sentiment. Domestically in Australia, markets are closely watching September quarter inflation data to be released later this month, as well as awaiting the Reserve Bank of Australia’s last two policy meetings of the year in November and December. On the day, tech stocks .AXIJ jumped as much as 3.1% after data center operator Firmus, backed by Nvidia NVDA.O, called off its IPO due to lukewarm market response. Maas Group MGH.AX, a 3.2% shareholder in Firmus, resumed trading after a morning halt and saw its shares plunge as much as 10.7%. David Tuckwell, Chief Investment Officer at ETF Shares, said Firmus’s withdrawal was positive for local tech stocks as it kept fund managers’ money in existing listed shares and avoided forced rebalancing for index funds. He added that after extended selling, valuations in the sector were oversold and now operating on their own momentum. However, weak demand for Firmus indicated that investors preferred enterprises with solid performance, rather than shunning tech stocks entirely. WiseTech Global WTC.AX, Xero XRO.AX, and Life360 360.AX rose 4.2%, 3.5%, and 4.1% respectively. As gold prices edged up, gold miners .AXGD gained 1.9%, the sector's biggest gain in more than two weeks. GOL/ Weighed down by softer iron ore and copper prices, the overall mining index dipped 0.2%. IRONORE/ MET/L Financial stocks .AXFJ rebounded 0.5% after declines over the previous two sessions. Energy stocks .AXEJ edged higher by 0.2%, marking four straight gains despite weaker early oil prices. O/R Across the Tasman Sea, New Zealand’s S&P/NZX 50 index .NZ50 closed up 0.4% at 13,749.35 points. (For the convenience of non-English speakers, Reuters automatically translates its reports into several languages. Due to possible errors or omitted context in automated translations, Reuters does not guarantee the accuracy of such texts and provides them solely for reader convenience. Reuters accepts no liability for any damages or losses resulting from the use of automated translation features.) For more on "Schedules & Data": US earnings calendar RESF/US, Wall Street outlook for the week .N/O, Global economic outlook DATA/ ... See all the latest market headlines and breaking news at NEWS1.

路透社•2026/10/09 05:56